Trial · NCT07445295
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT07445295, Phase 3, Not yet recruiting, Chipscreen Biosciences, Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Trials, record NCT07445295. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07445295
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- NCT number
- NCT07445295
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 558 participants, estimated
- Lead sponsor
- Chipscreen Biosciences, Ltd.
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Chiauranib, Toripalimab Injection, Albumin-paclitaxel Injection, Gemcitabine Injection, Chiauranib placebo, Toripalimab Injection placebo
- First posted
- 2026-03-03
- Last updated
- 2026-03-03
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of adverse events | Run-in period.From the enrollment until 28 days after the last dose | Defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAEV5.0) |
| Primary | OS | Randomized controlled period. From the first dose to death or end of study, an average of 2 year | Overall survival |
| Secondary | ORR | Run-in period and Randomized controlled period. From the first dose to disease progression or end of study, an average of 2 year | Objective Response Rate |
| Secondary | DoR | Run-in period and Randomized controlled period. From the first dose to disease progression or end of study, an average of 2 year | Duration of Response |
| Secondary | DCR | Run-in period and Randomized controlled period. From the first dose to disease progression or end of study, an average of 2 year | Disease control rate |
| Secondary | PFS | Run-in period and Randomized controlled period. From the first dose to disease progression or end of study, an average of 2 year | Progression free survival |
| Secondary | OS | Run-in period. From the first dose to death or end of study, an average of 2 year | Overall survival |
| Secondary | TTR | Randomized controlled period. From the first dose to disease progression or end of study, an average of 2 year | Time to Response |
| Secondary | Incidence and severity of adverse events | Randomized controlled period. From the enrollment until 28 days after the last dose | Defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAEV5.0) |
| Secondary | QoL | Randomized controlled period. From the first dose to disease progression or end of study, an average of 2year | Quality of Life assessed by EORTC Quality of Life Questionnaire-Pancreatic Cancer Module 26 (EORTC QLQ-PAN26). The scale consists of 26 items, covering 14 dimensions including pain, indigestion, and satisfaction with healthcare, with scores ranging from 0 to 100. For symptom dimensions, higher scores indicate more severe symptoms; for functional/psychological dimensions, higher scores reflect better functioning or greater satisfaction. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07445295
GET https://conductscience.org/api/trials/v1/NCT07445295/registered